Lyumjev (insulin lispro-aabc) is Eli Lilly’s ultra-rapid mealtime insulin, approved by the FDA in June 2020 for adults with type 1 (T1D) and type 2 (T2D) diabetes and expanded to pediatric T1D in 2024. It contains the same insulin lispro molecule as Humalog but includes two added excipients — treprostinil and citrate — that accelerate subcutaneous absorption and produce a faster post-injection insulin peak.
How Lyumjev Was Designed
Standard mealtime analogs like Humalog and NovoLog start working in roughly 15 minutes after subcutaneous injection. The delay reflects the time it takes for hexameric insulin to dissociate, diffuse into surrounding tissue, and enter capillaries. Lyumjev’s two added excipients address this directly:
- Treprostinil — a vasodilator that increases local capillary blood flow and speeds insulin uptake.
- Citrate — increases local vascular permeability and aids absorption.
The result is appearance of lispro in the bloodstream within 1-3 minutes after injection, compared with about 15 minutes for Humalog.
Lyumjev vs Humalog vs Fiasp
| Feature | Humalog | Lyumjev | Fiasp |
|---|---|---|---|
| Molecule | Insulin lispro | Insulin lispro-aabc | Insulin aspart with niacinamide |
| Manufacturer | Lilly | Lilly | Novo Nordisk |
| Onset | ~15 min | ~1-3 min | ~2-5 min |
| Peak | ~1-2 hr | ~1-2 hr | ~1-2 hr |
| Mealtime window | 15 min before meal | At meal start to 20 min after | Within 20 min of meal start |
| Pump approved | Yes | Yes | Yes (with monitoring) |
FDA-Approved Uses
Lyumjev is approved for:
- Improving glycemic control in adults with T1D and T2D.
- Pediatric patients age 1 and older with T1D (since 2024).
- Subcutaneous injection by KwikPen, U-100 vial, or U-200 KwikPen.
- Continuous subcutaneous infusion via insulin pump.
Lyumjev is also approved for intravenous use in healthcare settings, though IV use is less common in routine practice.
Dosing and Practical Use
Lyumjev is dose-equivalent to Humalog: someone using 8 units of Humalog before lunch typically uses 8 units of Lyumjev. The total daily dose, basal-to-bolus split, and carbohydrate ratios are not changed when switching, though some users find their post-meal glucose spikes are smaller, prompting their prescriber to recalibrate ratios.
The mealtime window is the main practical difference. Lyumjev can be injected at the start of a meal or up to 20 minutes after starting to eat. This flexibility is helpful for:
- Children with unpredictable appetites.
- People on GLP-1 medications (Ozempic, Mounjaro) with reduced or variable hunger.
- Restaurant meals where serving timing is uncertain.
- Anyone who underdoses for safety and corrects up after eating.
Side Effects and Risks
- Hypoglycemia — the most common side effect of any rapid-acting insulin; faster onset means faster glucose drop.
- Injection or infusion site reactions — Lyumjev has higher reported rates than Humalog, likely due to treprostinil; users may experience redness, itching, or irritation, particularly in pumps.
- Weight gain — common to all insulin therapy.
- Hypokalemia — clinically relevant in hospitalized or high-dose use.
- Allergic reactions — rare but possible.
Pump users on Lyumjev sometimes need to change infusion sets every 2 days instead of 3 to limit site irritation. Discuss this with your pump trainer if you switch.
Cost and Access
Lyumjev is sold as KwikPen (U-100 and U-200) and U-100 vials. List prices are similar to Humalog, but Lilly’s $35-per-month savings card brings out-of-pocket cost down for most commercially insured patients. Medicare patients also benefit from the federal $35 monthly insulin cap. Check Lilly’s official savings card site for current eligibility.
Where Lyumjev Fits in Modern Care
Ultra-rapid insulins matter most for people who are not hitting time-in-range or postprandial glucose targets despite good basal control and accurate carb counting. They especially benefit insulin pump users running hybrid closed-loop systems, where faster insulin action improves algorithm responsiveness. For people newly diagnosed with prediabetes or early T2D, mealtime insulin is rarely needed — focus on the strategies in our treatment hub and track progress with the A1C test.
The Bottom Line
Lyumjev is an ultra-rapid mealtime insulin that delivers insulin lispro into the bloodstream within minutes, giving meaningful improvements in postprandial glucose control compared with Humalog. It is approved for adults and children with T1D and T2D, can be used in pumps and pens, and offers flexible meal-timing. Side effect profile is similar to Humalog with somewhat higher injection site reactions. Whether to switch from another rapid analog is a conversation worth having with your endocrinology team based on your time-in-range data and lifestyle.
